vimarsana.com
Home
Live Updates
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer : vimarsana.com
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer
Verastem Oncology announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine...
Related Keywords
Chicago
,
Illinois
,
United States
,
American
,
,
Eastern Cooperative Oncology Group
,
American Society Of Clinical Oncology
,
Verastem Oncology
,
American Society
,
Clinical Oncology
,
Annual Meeting
,
Performance Status
,
vimarsana.com © 2020. All Rights Reserved.